D. Boral Capital Reiterates Buy Rating for Cytosorbents (NASDAQ:CTSO)

D. Boral Capital reaffirmed their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research report sent to investors on Monday morning,Benzinga reports. D. Boral Capital currently has a $10.00 price target on the medical research company’s stock.

Several other research firms have also issued reports on CTSO. StockNews.com assumed coverage on Cytosorbents in a report on Monday. They set a “hold” rating on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Trading Up 3.8 %

Shares of CTSO stock opened at $1.08 on Monday. The stock has a 50 day simple moving average of $0.92 and a 200 day simple moving average of $1.03. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $1.59. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The stock has a market cap of $59.05 million, a P/E ratio of -3.00 and a beta of 0.58.

Hedge Funds Weigh In On Cytosorbents

Hedge funds and other institutional investors have recently modified their holdings of the business. Atomi Financial Group Inc. acquired a new stake in Cytosorbents in the third quarter valued at about $51,000. Geode Capital Management LLC lifted its holdings in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares during the last quarter. Finally, Sargent Investment Group LLC boosted its stake in shares of Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.